Patterns of use, desired effects, and mental health status of a sample of natural psychoactive drug users

References

• Alper, K.R. (2001). Ibogaine: A review. In The alkaloids. Chemistry and biology (Vol. 56, pp. 1–38). London: Academic Press/Elsevier. doi:10.1016/S0099-9598(01)56005-8
   Google Scholar
• Alper, K.R., Lotsof, H.S., Frenken, G., Luciano, D.J., & Bastiaans, J. (1999). Treatment of acute opioid withdrawal with ibogaine. The American Journal of Addictions, 8, 234–242. doi:10.1080/105504999305848
   PubMed Web of Science ®Google Scholar
• Andersson, C., Kristinsson, J., & Gry, J. (2009). Occurrence and use of hallucinogenic mushrooms containing psilocybin alkaloids. Copenhagen, Denmark: Nordic Council of Ministers.
   Google Scholar
• Andritzky, M. (1989). Sociopsychotherapeutic functions of ayahuasca healing in Amazonia. Journal of Psychoactive Drugs, 21, 77–89. doi:10.1080/02791072.1989.10472145
   PubMed Web of Science ®Google Scholar
• Apud, I., & Romaní, O. (2017). Medicine, religion and ayahuasca in Catalonia. Considering ayahuasca networks from a medical anthropology perspective. International Journal of Drug Policy, 39, 28–36. doi:10.1016/j.drugpo.2016.07.011
   PubMed Web of Science ®Google Scholar
• Bouso, J.C., González, D., Fondevila, S., Cutchet, M., Fernández, X., Barbosa, P.C.R., … Bouso, J.C. (2012). Personality, psychopathology, life attitudes and neuropsychological performance among ritual users of ayahuasca: A longitudinal study. PLoS One, 7, e42421. doi:10.1371/journal.pone.0042421
   PubMed Web of Science ®Google Scholar
• Carbonaro, T.M., Bradstreet, M.P., Barrett, F.S., MacLean, K.A., Jesse, R., Johnson, M.W., & Griffiths, R.R. (2016). Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences. Journal of Psychopharmacology, 30, 1268–1278. doi:10.1177/0269881116662634
   PubMed Web of Science ®Google Scholar
• Carhart-Harris, R.L., Roseman, L., Haijen, E., Erritzoe, D., Watts, R., Branchi, I., & Kaelen, M. (2018). Psychedelics and the essential importance of context. Journal of Psychopharmacology (Oxford), 32, 725–731. doi:10.1177/0269881118754710
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC). (2016). Current cigarette smoking among adults—United States, 2016. Retrieved from https://www.cdc.gov/tobacco/data_statistics/mmwrs/byyear/2018/mm6702a1/highlights.htm
   Google Scholar
• Corkery, J.M., Schifano, F., Oyefeso, S., Ghodse, A.H., Tonia, T., Naidoo, V., & Button, J. (2011). “Bundle of fun” or “bunch of problems”? Case series of khat-related deaths in UK. Drugs: Education, Prevention and Policy, 18, 408–425. doi:10.3109/09687637.2010.504200
   Web of Science ®Google Scholar
• Davis, A.K., Barsuglia, J.P., Lancelotta, R., Grant, R.M., & Renn, E. (2018). The epidemiology of 5-methoxy-N, N-dimethyltryptamine (5-MeO-DMT) use: Benefits, consequences, patterns of use, subjective effects, and reasons for consumption. Journal of Psychopharmacology, 32, 779–792. doi:10.1177/0269881118769063
   PubMed Web of Science ®Google Scholar
• dos Santos, R.G., Bouso, J.C., & Hallak, J.E.C. (2017). Ayahuasca, dimethyltryptamine, and psychosis: A systematic review of human studies. Therapeutic Advances in Psychopharmacology, 7, 141–157. doi:10.1177/2045125316689030
   PubMed Web of Science ®Google Scholar
• Elsey, J.W.B. (2017). Psychedelic drug use in healthy individuals: A review of benefits, costs, and implications for drug policy. Drug Science, Policy and Law, 3, 1–11. doi:10.1177/2050324517723232
   Google Scholar
• European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). (2012). Prevalence of daily cannabis use in the European Union and Norway, 2012. Retrieved from http://www.emcdda.europa.eu/system/files/publications/753/emcdda-daily-cannabis-use-2012_400271.pdf
   Google Scholar
• European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). (2018). Statistical bulletin 2018 — Prevalence of drug use. Retrieved from http://www.emcdda.europa.eu/data/stats2018/gps
   Google Scholar
• Frecksa, E., Bokor, P., & Winkelman, M. (2016). The therapeutic potentials of ayahuasca: Possible effects against various diseases of civilization. Frontiers in Pharmacology, 7, 35. doi:10.3389/fphar.2016.00035
   PubMed Web of Science ®Google Scholar
• Glennon, R.A., Titeler, M., & McKenney, J.D. (1984). Evidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents. Life Sciences, 35, 2505–2511. doi:10.1016/0024-3205(84)90436-3
   PubMed Web of Science ®Google Scholar
• Global Drug Survey (GDS). (2017). High in the USA. Retrieved from https://www.globaldrugsurvey.com/high-in-the-usa/
   Google Scholar
• Goldberg, D.P. (1972). The detection of psychiatric illness by questionnaire. London, UK: Oxford University Press.
   Google Scholar
• Goldberg, D.P., Gater, R., Sartorius, N., Ustun, T.B., Piccinelli, M., Gureje, O., & Rutter, C. (1997). The validity of two versions of the GHQ in the WHO study of mental illness in general health care. Psychological Medicine, 27, 191–197. doi:10.1017/S0033291796004242
   PubMed Web of Science ®Google Scholar
• González, D., Ventura, M., Caudevilla, F., Torrens, M., & Farré, M. (2013). Consumption of new psychoactive substances in a Spanish sample of research chemical users. Human Psychopharmacology, 28, 332–340. doi:10.1002/hup.2323
   PubMed Web of Science ®Google Scholar
• Griffin, O.H., Miller, B.L., & Khey, D.N. (2008). Legally high? Legal considerations of Salvia divinorum. Journal of Psychoactive Drugs, 40, 183–191. doi:10.1080/02791072.2008.10400629
   PubMed Web of Science ®Google Scholar
• Griffiths, R.R., Johnson, M.W., Richards, W.A., Richards, B.D., McCann, U., & Jesse, R. (2011). Psilocybin occasioned mystical-type experiences: Immediate and persisting dose-related effects. Psychopharmacology (Berl), 218, 649–665. doi:10.1007/s00213-011-2358-5
   PubMed Web of Science ®Google Scholar
• Hallok, R.M., Dean, A., Knecht, Z.A., Spencer, J., & Taverna, E.C. (2013). A survey of hallucinogenic mushroom use, factors related to usage, and perceptions of use among college students. Drug and Alcohol Dependence, 130, 245–248. doi:10.1016/j.drugalcdep.2012.11.010
   PubMed Web of Science ®Google Scholar
• Halpern, J.H., & Sewell, R.A. (2005). Hallucinogenic botanicals of America: A growing need for focused drug education and research. Life Sciences, 78, 519–526. doi:10.1016/j.lfs.2005.09.005
   PubMed Web of Science ®Google Scholar
• Halpern, J.H., Sherwood, A.R., Passie, T., Blackwell, K.C., & Ruttenber, A.J. (2008). Evidence of health and safety in American members of a religion who use a hallucinogenic sacrament. Medical Science Monitor, 14, 15–22.
   Web of Science ®Google Scholar
• Harvey, G., & Wallis, R.J. (2015). Historical dictionary of shamanism. Maryland, US: Rowman & Littlefield Publishers.
   Google Scholar
• Heinrich, M. (2010). Ethnopharmacology and drug development. In L Mander & H. W. Lui (Eds.), Comprehensive natural products II: Chemistry and biology. Oxford, UK: Elsevier.
   Google Scholar
• Heise, C.W., & Brooks, D.E. (2016). Ayahuasca exposure: Descriptive analysis of calls to US Poison Control Centers from 2005 to 2015. Journal of Medical Toxicology, 13, 245–248. doi:10.1007/s13181-016-0593-1
   PubMed Web of Science ®Google Scholar
• Helander, A., & Bäckberg, M. (2018). Epidemiology of NPS based confirmed overdose cases: The STRIDA project. Handbook of Experimental Pharmacology, 252, 461–473. doi:10.1007/164_2018_134
   PubMedGoogle Scholar
• Hendricks, P.S., Thorne, C.B., Clark, C.B., Coombs, D.W., & Johnson, M.W. (2015). Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population. Journal of Psychopharmacology, 29, 280–288. doi:10.1177/0269881114565653
   PubMed Web of Science ®Google Scholar
• Krebs, T.S., & Johansen, P.Ø. (2013). Over 30 million psychedelic users in the United States. F1000Research, 2, 98. doi:10.12688/f1000research.2-98.v1
   PubMedGoogle Scholar
• Maqueda, A.E., Valle, M., Addy, P.H., Antonijoan, R.M., Puntes, M., Coimbra, J., … Riba, J. (2016). Naltrexone but not ketanserin antagonizes the subjective, cardiovascular, and neuroendocrine effects of salvinorin-A in humans. International Journal of Neuropsychopharmacology, 19, pyw016. doi:10.1093/ijnp/pyw016
   PubMed Web of Science ®Google Scholar
• McKenna, D.J., & Towers, G.H. (1984). Biochemistry and pharmacology of tryptamines and beta-carbolines. A minireview. Journal of Psychoactive Drugs, 16, 347–358. doi:10.1080/02791072.1984.10472305
   PubMed Web of Science ®Google Scholar
• Nielen, R.J., van der Heijden, F.M., Tuinier, S., & Verhoeven, W.M. (2004). Khat and mushrooms associated with psychosis. The World Journal of Biological Psychiatry, 5, 49–53. doi:10.1080/15622970410029908
   PubMed Web of Science ®Google Scholar
• Nutt, D.J., King, L.A., & Philips, L.D. (2010). Drug harms in the UK: A multicriteria decision analysis. Lancet, 6736, 61462–61466. doi:10.1016/S0140-6736(10)61462-6
   Google Scholar
• Orsolini, L., John-Smith, P., McQueen, D., Papanti, D., Corkery, J., & Schifano, F. (2017). Evolutionary considerations on the emerging subculture of the E-psychonauts and the novel psychoactive substances: A comeback to the shamanism? Current Neuropharmacology, 15, 731–737. doi:10.2174/1570159X15666161111114838
   PubMed Web of Science ®Google Scholar
• Palamar, J.J., & Le, A. (2018). Trends in DMT and other tryptamine use among young adults in the United States. The American Journal on Addictions, 27, 578–585. doi:10.1111/ajad.12803
   PubMed Web of Science ®Google Scholar
• Palamar, J.J., Martins, S.S., Su, M.K., & Ompad, D.C. (2015). Self-reported use of novel psychoactive substances in a US nationally representative survey: Prevalence, correlates, and a call for new survey methods to prevent underreporting. Drug and Alcohol Dependence, 156, 112–119. doi:10.1016/j.drugalcdep.2015.08.028
   PubMed Web of Science ®Google Scholar
• Riley, S.C., & Blackman, G. (2008). Between prohibitions: Patterns and meanings of magic mushroom use in the UK. Substance Use and Misuse, 43, 55–71. doi:10.1080/10826080701772363
   PubMed Web of Science ®Google Scholar
• Shalit, N., Rehm, J., & Lev-Ran, S. (2019). Epidemiology of hallucinogen use in the U.S. results from the national epidemiologic survey on alcohol and related conditions III. Addictive Behaviors, 89, 35–43. doi:10.1016/j.addbeh.2018.09.020
   PubMed Web of Science ®Google Scholar
• Soussan, C., & Kjellgren, A. (2016). The users of novel psychoactive substances: Online survey about their characteristics, attitudes and motivations. International Journal of Drug Policy, 32, 77–84. doi:10.1016/j.drugpo.2016.03.007
   PubMed Web of Science ®Google Scholar
• Substance Abuse and Mental Health Services Administration. National Survey on Drug Use and Health (NSDUH). (2015). Table 2.41B—Alcohol Use in Lifetime, Past Year, and Past Month among Persons Aged 12 or Older, by Demographic Characteristics: Percentages, 2014 and 2015. Available at https://www.samhsa.gov/data/sites/default/files/NSDUH-DetTabs-2015/NSDUH-DetTabs-2015/NSDUH-DetTabs-2015.htm#tab2-41b
   Google Scholar
• Sumnall, H.R., Measham, F., Brandt, S.D., & Cole, J.C. (2011). Salvia divinorum use and phenomenology: Results from an online survey. Journal of Psychopharmacology (Oxford), 25, 1496–1507. doi:10.1177/0269881110385596
   PubMed Web of Science ®Google Scholar
• Talin, P., & Sanabria, E. (2017). Ayahuasca’s entwined efficacy: An ethnographic study of ritual healing from ‘addiction’. International Journal of Drug Policy, 44, 23–30. doi:10.1016/j.drugpo.2017.02.017
   PubMed Web of Science ®Google Scholar
• van Amsterdam, J., Opperhuizen, A., & van den Brink, W. (2011). Harm potential of magic mushroom use: A review. Regulatory Toxicology and Pharmacology, 59, 423–429. doi:10.1016/j.yrtph.2011.01.006
   PubMed Web of Science ®Google Scholar
• World Health Organization (WHO). (2018). Tobacco. Data and statistics, 2018. Retrieved from http://www.euro.who.int/en/health-topics/disease-prevention/tobacco/data-and-statistics
   Google Scholar
• Wu, L.T., Woody, G.E., Yang, C., Li, J.H., & Blazer, D.G. (2011). Recent national trends in Salvia divinorum use and substance-use disorders among recent and former Salvia divinorum users compared with nonusers. Substance Abuse and Rehabilitation, 2, 53–68. doi:10.2147/SAR.S17192
   Google Scholar